logo

Liminal Biosciences Inc. (LMNL)



Trade LMNL now with
  Date
  Headline
11/8/2020 7:32:36 PM Liminal BioSciences FDA Extends Review Period For Ryplazim BLA To June 5, 2021 From March 5, 2021
10/30/2020 8:34:27 AM Liminal BioSciences Announces Private Placement Financing Of $30 Mln
9/21/2020 8:22:06 AM Liminal BioScience : FDA Assigns PDUFA Target Action Date Of March 5
9/8/2020 6:05:26 AM Liminal BioSciences Announces Resubmission Of BLA For Ryplazim For Treatment Of Congenital Plasminogen Deficiency
1/13/2020 7:00:00 AM Liminal BioSciences Outlines Corporate Priorities for 2020 (Press Release)
6/14/2019 3:34:30 AM Prometic Announces Four Abstracts Highlighting Progress In Developing PBI-4050
12/19/2018 7:32:29 AM Prometic Life Sciences Names Simon Best As Interim CEO; Pierre Laurin Has Stepped Down
8/7/2018 7:13:14 AM Prometic Receives Rare Pediatric Disease Designation From FDA For Small Molecule Drug Candidate, PBI-4050
4/30/2018 6:33:39 AM Prometic Reports Positive Clinical Data From IVIG Pivotal Phase 3 Trial; Meets Primary And Secondary Endpoints